The Canadian Cancer Research Alliance

BioCanRx, Canada’s Immunotherapy Network, is launching its first Open Call for Research Proposals, made possible by funding from the Strategic Science Fund. By funding the selected proposals, BioCanRx will increase support for multi-disciplinary cancer immunotherapy and biotherapeutic approaches. More information is available here: https://biocanrx.com/research/research-program/open-call-2024

On behalf of the Alliance, a group of CCRA members formulated a response to a statement issued by the Ministers of Innovation, Science and Industry and Health to the presidents of Canada’s federal research funding agencies on June 17, 2024, which asked for input from the research community on the proposed re-structuring of the federal research support system and the introduction of the capstone organization. CCRA's response (here) was submitted on July 17th and highlighted three consideration...

In December 2023, it was announced that Canada’s Drug Agency would be built from CADTH. The work of the drug agency expands on CADTH’s existing mandate and functions — which spans drugs, medical devices, and clinical interventions — and includes new work streams such as: improving the appropriate prescribing and use of medications increasing pan-Canadian data collection and expanding access to drug and treatment data, including real-world evidence data reducing drug system duplicat...

The Canadian Cancer Clinical Trials Network (3CTN) and its collaborative partners are thrilled to announce the launch of an Equity, Diversity, and Inclusion (EDI) Framework and companion Toolkit designed to support the Canadian research community in embedding EDI best practices within clinical trial conduct! This comprehensive EDI Framework and Toolkit resource are the products of an expert working group comprised of 3CTN members, trial sponsors, and people with lived experience from underrep...